Directly observed therapy (DOT) for tuberculosis: Why, when, how and if?

Thorax

Volumn 54, Issue SUPPL. 2, 1999, Pages

  Ormerod, L Peter ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF CARE; SHORT SURVEY; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0032799002     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.2008.s42     Document Type: Short Survey

References (53)

1. 1 Global Tuberculosis Programme. Treatment of tuberculosis. Geneva: WHO, 1997: Report WHO/TB/97.220.
2. 2 World Health Organisation. Press release, 21 March 1997, WHO/24.
3. 3 Chaulk CP, Kazanjjian VH. DOT for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998;27:943-8.
4. 4 Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed therapy for tuberculosis. Lancet 1998;352:1340-3.
5. 5 China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112842 Chinese patients with smear-positive tuberculosis. Lancet 1996;347:358-62.
6. 6 Neher A, Breyer G, Shrestha B, et al. Directly observed intermittent short-course chemotherapy in the Katmandu Valley. Tuberc Lung Dis 1996;77:302-7.
7. 7 Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ 1997;315:1403-6.
8. 8 Fox W. The problems of self-administration of drugs: with particular reference to pulmonary tuberculosis. Tubercle 1958;39:269-74.
9. 9 Hong Kong Tuberculosis Treatment Service/British Medical Research Council. A study in Hong Kong to evaluate the role of pretreatment susceptibility tests in the selection of regimens of chemotherapy for pulmonary tuberculosis. Second report. Tubercle 1974;55:169-92.
10. 10 Ormerod LP, Prescott RJ. Interrelations between relapses, drug regimens and compliance with treatment in tuberculosis. Respir Med 1991;85: 239-42.
11. 11 Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis - I. BMJ 1983;287:33-5.
12. 12 Fox W. Compliance of patients and physicians: experience and lessons from tuberculous II. BMJ 1983;287:101-5.
13. 13 Medical Research Council Tuberculosis and Chest Diseases Unit. Treatment of pulmonary tuberculosis in patients notified in England and Wales in 1978-9; chemotherapy and hospital admission. Thorax 1985;40:113-20.
14. 14 Darbyshire JH, Byfield SP, Nunn AJ, et al. Results of treatment of adults with pulmonary tuberculosis in England and Wales notified in 1983. Thorax 1987;42:222-5.
15. 15 British Thoracic Society Research Committee and Medical Research Council Cardiothoracic Epidemiology Group. The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. Respir Med 1991;85:319-23.
16. 16 Ormerod LP, Bentley C, The management of pulmonary tuberculosis notified in England and Wales in 1993. J R Coll Phys Lond 1997;31: 662-5.
17. 17 Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48.
18. 18 International Union Against Tuberculosis and Lung Disease (IUATLD). Antituberculosis regimens of chemotherapy. Recommendation from the committee on treatment of the IUATLD. Bull Int Union Tuberc Lung Dis 1988;63:60-4.
19. 19 World Health Organisation Tuberculosis Unit, Division of Communicable Diseases. Guidelines for tuberculosis treatment in adults and children in national treatment programmes. Geneva: WHO, 1991: 1-61.
20. 20 American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149: 1359-74.
21. 21 Chaulk CP, Rice-Moore R, Rizzo R, et al. Eleven years of community based directly observed therapy for tuberculosis. JAMA 1995;274: 945-51.
22. 22 Fox W. Self-administration of medicaments: a review of published work and a study of the problems. Bull Int Union Tuberc 1962;32:307-31.
23. 23 Tuberculosis Chemotherapy Centre Madras. A concurrent comparison of intermittent (twice weekly) isoniazid and streptomycin and daily isoniazid and PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Org 1964;31:247-71.
24. 24 Moodie AS. Mass ambulatory chemotherapy in the treatment of tuberculosis in a predominantly urban community. Am Rev Respir Dis 1967; 95:384-97.
25. 25 Stradling P, Poole G. Self-medication in tuberculosis. Lancet 1958;ii: 1066-7.
26. 26 Stradling P, Poole G. Towards fool-proof chemotherapy for tuberculosis. Tubercle 1963;44:71-5.
27. 27 Moulding T. New responsibilities for health departments and public health nurses in tuberculosis: keeping the outpatient on therapy. Am J Publ Health 1966;56:416-27.
28. 28 Sbarbaro JA, Johnson S. Tuberculous chemotherapy for recalcitrant outpatients administered twice weekly. Am Rev Respir Dis 1968;97: 895-903.
29. 29 Sbarbaro JA. Compliance: inducements and enforcements. Chest 1979; 6(Suppl):750-6.
30. 30 Sbarbaro JA. Public health aspects of tuberculosis: supervision of therapy. Clin Chest Med 1980;1:253-63.
31. 31 American Thoracic Society. Guidelines for short-course tuberculosis chemotherapy. Am Rev Respir Dis 1980;212:611-4.
32. 32 American Thoracic Society. Standard therapy for tuberculosis 1985. Chest 1985;87:17-24S.
33. 33 Advisory Council for the Elimination of Tuberculosis. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42:RR/7.
34. 34 Davidow A, Marmor M, Alcabes P. Geographical diversity in tuberculosis trends and directly observed therapy, New York City, 1991 to 1994. Am J Respir Crit Care Med 1997;156:1495-500.
35. 35 Bechan S, Connolly C, Short GM, et al. Directly observed therapy for tuberculosis given twice weekly in the workplace in urban South Africa. Trans R Soc Trop Med Hyg 1997;91:704-7.
36. 36 Chowdhury AMR, Chowdhury S, Islam MN, et al. Control of tuberculosis by community health workers in Bangladesh. Lancet 1997; 350:169-72.
37. 37 Davidson RL. A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States. Chest 1998;114:1239-43.
38. 38 Cao JP, Zhang LY, Zhu JQ, et al. Two-year follow-up of directly observed intermittent regimens for smear-positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 1998;2:360-4.
39. 39 Smirnoff M, Goldberg R, Indyk L, et al. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis 1998;2:134-9.
40. 40 Weiss SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
41. 41 Salomon N, Periman DC, Rubenstein A, et al. Implementation of universal directly observed therapy at a New York City Hospital and evaluation of an outpatient directly observed therapy program. Int J Tuberc Lung Dis 1997;1:397-404.
42. 42 Burman WJ, Dalton CB, Cohn DL, et al. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997;112:63-70.
43. 43 Moore RD, Chaulk PC, Griffiths R, et al. Cost-effectiveness of directly observed versus self-administered treatment for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-9.
44. 44 Floyd K, Wilkinson D, Gilks C. Comparison of cost-effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. BMJ 1997;315:1407-11.
45. 45 Wilkinson D, Floyd K, Gilks C. Costs and cost-effectiveness of alternative tuberculosis management strategies in South Africa: implications for policy. S Afr Med J 1997;87:451-5.
46. 46 Cohn DL, Carlin BJ, Peterson KL, et al. A 62-dose therapy for pulmonary and extra-pulmonary TB. A twice-weekly directly observed and cost-effective regimen. Ann Intern Med 1990;112:407-15.
47. 47 Wilkinson D, Davies GR. Coping with Africas increasing tuberculosis burden: are community supervisors an essential component of the DOTS strategy? Trop Med ha Int Health 1997;2:700-4.
48. 48 Sonnenberg P, Ross MH, Shearer SCPM, et al. The effect of dosage cards on compliance with directly observed therapy in hospital. Int J Tuberc Lung Dis 1998;2:168-71.
49. 49 Fryatt RJ. Review of published cost-effectiveness studies on tuberculosis treatment programmes. Int J Tuberc Lung Dis 1997;1:101-9.
50. 50 Garner P. What makes DOT work?. Lancet 1998;352:1326-7.
51. 51 Garner P, Volmink J. Directly observed therapy. Lancet 1997;350:666-7.
52. 52 Grange J, Zumla A. Making DOT succeed. Lancet 1997;350:157.
53. 53 Bayer R, Stayton C, Desvarieux M, et al. Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary? Am J Public Health 1998;88:1052-8.